42 / 76
CARDIOVASCULAR JOURNAL OF AFRICA • Volume 29, No 4, July/August 2018
240
AFRICA
Statistics Subcommittee. Executive Summary: Heart Disease and
Stroke Statistics –2016 Update: A Report from the American Heart
Association.
Circulation
2016;
133
(4): 447–454.
3.
Bradshaw D, Laubscher R, Schneider M. Estimated cause of death
profiles for the nine new provinces based on 1990 data, Tygerberg.
Medical Research Council, Cape Town, South Africa, 1995.
4.
Lozano R, Naghavi M, Foreman K,
et al
. Global and regional mortality
from 235 causes of death for 20 age groups in 1990 and 2010: a system-
atic analysis for the Global Burden of Disease Study 2010.
Lancet
2012;
380
(9859): 2095–2128.
5.
Beers MH, Berkow R (eds).
The Merck Manual of Diagnosis and
Therapy.
17th edn. New Jersey: Merck Research Laboratories, 1999:
1662.
6.
Conti CR. Re-thinking angina.
Clin Cardiol
2007;
30
(2 Suppl 1): I1–3.
7.
Al-Lamee R, Davies J, Malik IS. What is the role of coronary angio-
plasty and stenting in stable angina?
Br Med J
2016;
352
: i205.
8.
Braunwald E, Morrow DA. Unstable angina: is it time for a requiem?
Circulation
2013;
127
(24): 2452–2457.
9.
Republic of South Africa.
Essential Drugs Programme
.
Hospital Level
(Adults) Standard Treatment Guidelines and Essential Medicines List
.
4th edn. Republic of South Africa: National Department of Health,
2015.
10. Siama K, Tousoulis D, Papageorgiou N, Siasos G, Tsiamis E,
Bakogiannis C,
et al
. Stable angina pectoris: current medical treatment.
Curr Pharmaceut Design
2013;
19
(9): 1569–1580.
11. Thadani U. Management of stable angina – current guidelines: a critical
appraisal.
Cardiovasc Drugs Ther
2016;
30
(4): 419–426.
12. Patel AV, Bangalore S. Challenges with evidence-based management of
stable ischemic heart disease.
Curr Cardiol Rep
2017;
19
(2): 11.
13. Pepine CJ, Wolff AA. A controlled trial with a novel anti-ischemic
agent, ranolazine, in chronic stable angina pectoris that is responsive to
conventional antianginal agents. Ranolazine Study Group.
Am J Cardiol
1999;
84
(1): 46–50.
14. IONA Study Group. Effect of nicorandil on coronary events in
patients with stable angina: the impact of nicorandil in angina (IONA)
randomised trial.
Lancet
2002;
359
: 1269–1275.
15. Ohman EM. Chronic stable angina.
New Engl J Med
2016;
374
(12):
1167–1176.
16. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey
DE Jr,
et al.
; American College of Cardiology Foundation/American
Heart Association Task Force on Practice Guidelines.
Circulation
2013;
127
(23): e663–e828.
17. Malhotra A. The whole truth about coronary stents: the elephant in the
room.
J Am Med Assoc Intern Med
2014;
174
(8): 1367–1368.
18. Feldman DN, Gade CL, Slotwiner AJ, Parikh M, Bergman G, Wong
SC,
et al.
; New York State Angioplasty Registry. Comparison of
outcomes of percutaneous coronary interventions in patients of three
age groups (
<
60, 60 to 80, and > 80 years) (from the New York State
Angioplasty Registry).
Am J Cardiol
2006;
98
(10): 1334–1339.
19. Boden WE, O’Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk
WJ,
et al.
; COURAGE Trial Research Group. Optimal medical therapy
with or without PCI for stable coronary disease.
New Engl J Med
2007;
356
(15): 1503–1516.
20. Leek JT, Peng RD. Statistics. What is the question?
Science
2015;
347
(6228): 1314–1315.
21. Bangalore S, Pursnani S, Kumar S, Bagos PG. Percutaneous coronary
intervention versus optimal medical therapy for prevention of spontane-
ous myocardial infarction in subjects with stable ischemic heart disease.
Circulation
2013;
127
(7): 769–781.
22. Iqbal J, Widmer R, Gersh BJ. State of the art: optimal medical therapy
– competing with or complementary to revascularisation in patients with
coronary artery disease?
EuroIntervention
2017;
13
(6): 751–759.
23. Won H, Her AY, Kim BK, Kim YH, Shin DH, Kim JS,
et al
.
Percutaneous coronary intervention is more beneficial than optimal
medical therapy in elderly patients with angina pectoris.
Yonsei Med J
2016;
57
(2): 382– 387.
24. Bodenheimer T. The American health care system; the movement for
improved quality in health care.
New Engl J Med
1999;
340
: 488–492.
25. Bosse G, Breuer JP, Spies C. The resistance to changing guidelines –
what are the challenges and how to meet them.
Best Pract Res Clin
Anaesthesiol
2006;
20
(3): 379–395.
26. Grol R, Grimshaw J. From best evidence to best practice: effective
implementation of change in patients’ care.
Lancet
2003;
362
(9391):
1225–1230.
27. Grol R. Improving the quality of medical care: building bridges among
professional pride, payer profit, and patient satisfaction.
J Am Med
Assoc
2001;
286
(20): 2578–2585.
28. Mohee K, Wheatcroft SB. Optimal medical therapy and percutaneous
coronary intervention for stable angina: why patients should ‘be taking’
and ‘keep taking’ the tablets.
J Clin Pharmacol Therapeut
2014;
39
(4):
331–333.
29. Foucrier A, Rodseth R, Aissaoui M, Ibanes C, Goarin JP, Landais P,
et al
. The long-term impact of early cardiovascular therapy intensifica-
tion for postoperative troponin elevation after major vascular surgery.
Anaesth Analges
2014;
119
(5): 1053–1063.
30. Ilashchuk T, Glubochenko O, Senyuk B, Bachuk-Ponich N, Lukashevich
I. Influence of beta-blockers and ivabradine on long-term prognosis of
patients with stable angina.
Georgian Med News
2017;
267
: 57–61.